Delving into the Latest Updates on Kuros Biosurgery AG with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Biological products	1

Top 5 Target	Count

PTH1R(Parathyroid hormone receptor)	1

A Prospective, Randomized, Multi-Center Study to Assess the Safety and Performance of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers (DBX or Grafton) Mixed with Local Autograft in Patients Undergoing One to Two-Level Instrumented Posterolateral Lumbar/Thoracolumbar Fusion (PLF)

This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.

Start Date06 Dec 2024

Sponsor / Collaborator

Kuros Biosurgery AG

[+2]

NCT05037968

/ RecruitingNot Applicable

A Prospective, Randomized, Multi-center Study to Assess the Performance of MagnEtOs Flex Matrix Mixed with Local Autograft Compared to Trinity Elite Mixed with Local Autograft in Patients Undergoing Up to Four-level Instrumented PoSterolatEral Lumbar/thoraco-lumbar Fusion (PLF)

This is a phase IV post-marketing study for MagnetOs Flex Matrix. MagnetOs Flex Matrix is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease and undergoing spinal fusion surgery.
In this study, MagnetOs Flex Matrix will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.
Trinity Elite will also be used according to its latest IFU approved in the US. Specifically, this cellular based allograft is an allograft intended for the treatment of musculoskeletal defects.

Start Date10 Jun 2024

Sponsor / Collaborator

Kuros Biosurgery AG

[+1]

NCT04679896

/ CompletedNot Applicable

A Prospective, Randomized, Single-center Study to Assess the Performance of MagnetOs Putty Compared to Local Autograft in Patients Undergoing up to Three-level Instrumented Posterolateral Lumbar Fusion (PLF).

This is a phase IV post-marketing study for MagnetOs Putty. MagnetOs Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with leg pain and/or back pain and undergoing spinal fusion surgery.
In this study, MagnetOs Putty will be used according to the latest U.S. Instructions For Use, specifically as a bone graft extender mixed with autograft in a 1:1 vol.% in the posterolateral spine.

Start Date13 Aug 2021

Sponsor / Collaborator

Kuros Biosurgery AG

[+2]

100 Clinical Results associated with Kuros Biosurgery AG

Login to view more data

0 Patents (Medical) associated with Kuros Biosurgery AG

Login to view more data

1

Literatures (Medical) associated with Kuros Biosurgery AG

Journal of Biomedical Materials Research, Part B: Applied Biomaterials

Reduction in postlaminectomy epidural adhesions in sheep using a fibrin sealant-based medicated adhesion barrier

Author: Turner, A. Simon ; Mark, Silke ; Gisler, Serge M. ; Nuss, Katja ; Kraft, Susan ; Seim, Howard B. III ; Richards, Peter J. ; Schense, Jason

Epidural adhesion formation is believed to be a central governing factor in the prevalence of pain after spinal surgery and is regarded as being the primary instigator of neural tethering, leading to complications during revision surgery.In this study, we assess the effectiveness and safety of fibrin sealant supplemented with tributyrin, termed Medicated Adhesion Barrier (MAB), as an alternative means of reducing the incidence of posterior spinal epidural adhesion formation.Laminectomy defects in sheep were treated with MAB, fibrin sealant alone, ADCON Gel, or remained untreated.At 12 wk postoperatively, the extent of fibrosis and epidural adhesion formation was evaluated using magnetic resonance imaging (MRI), peel-off testing, and histol. examinationInitial in vitro anal. revealed that tributyrin was retained in fibrin gel in a time-dependent manner and was an effective inhibitor of fibroblast proliferation.Treatment of sheep with MAB significantly reduced both the prevalence (p < 0.05) and tenacity (p < 0.05) of epidural adhesions.The effectiveness of MAB in preventing epidural adhesions was found to be comparable with that of ADCON Gel.No adverse events were reported after the use of MAB.The MAB preparation seems to be an effective resorbable barrier for the prevention of epidural adhesions.

100 Deals associated with Kuros Biosurgery AG

Login to view more data

100 Translational Medicine associated with Kuros Biosurgery AG

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

8

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KUR-113 ( PTH1R )	Intervertebral Disc Degeneration More	Phase 2
KUR-112 ( PTH1R )	Bone Cysts More	Discontinued
KUR-116	Spinal Diseases More	Pending
KUR-211 ( Fibrinogen x PDGFR )	Diabetic foot ulcer More	Pending
KUR-111 ( PTH1R )	Fractures, Bone More	Pending